Evidence map›Paper›PMID 38621402›Full record

ArticleThe Lancet. Oncology2024

Advisory Group recommendations on priorities for the IARC Monographs.

Amy Berrington de González, Scott A Masten, Parveen Bhatti, Renée Turzanski Fortner, Susan Peters, Tiina Santonen, Marianna G Yakubovskaya, Robert Barouki, Silvia B M Barros, Dinesh Barupal and 36 more

Abstract read
In one paragraph

Article in The Lancet. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Light pollution: environmental and health impacts at high latitudes.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

46 authors.

Amy Berrington de GonzálezInternational Agency for Research on Cancer, Lyon, France.
Scott A MastenInternational Agency for Research on Cancer, Lyon, France.
Parveen BhattiInternational Agency for Research on Cancer, Lyon, France.
Renée Turzanski FortnerInternational Agency for Research on Cancer, Lyon, France.
Susan PetersInternational Agency for Research on Cancer, Lyon, France.
Tiina SantonenInternational Agency for Research on Cancer, Lyon, France.
Marianna G YakubovskayaInternational Agency for Research on Cancer, Lyon, France.
Robert BaroukiInternational Agency for Research on Cancer, Lyon, France.
Silvia B M BarrosInternational Agency for Research on Cancer, Lyon, France.
Dinesh BarupalInternational Agency for Research on Cancer, Lyon, France.
Laura E Beane FreemanInternational Agency for Research on Cancer, Lyon, France.
Gloria M CalafInternational Agency for Research on Cancer, Lyon, France.
Joakim DillnerInternational Agency for Research on Cancer, Lyon, France.
Karima El RhaziInternational Agency for Research on Cancer, Lyon, France.
Lin FritschiInternational Agency for Research on Cancer, Lyon, France.
Shoji FukushimaInternational Agency for Research on Cancer, Lyon, France.
Lode GodderisInternational Agency for Research on Cancer, Lyon, France.
Manolis KogevinasInternational Agency for Research on Cancer, Lyon, France.
Dirk W LachenmeierInternational Agency for Research on Cancer, Lyon, France.
Daniele MandrioliInternational Agency for Research on Cancer, Lyon, France.
Mazvita M MuchengetiInternational Agency for Research on Cancer, Lyon, France.
Richard T NiemeierInternational Agency for Research on Cancer, Lyon, France.
Jane J PappasInternational Agency for Research on Cancer, Lyon, France.
Jingbo PiInternational Agency for Research on Cancer, Lyon, France.
Mark P PurdueInternational Agency for Research on Cancer, Lyon, France.
Elio RiboliInternational Agency for Research on Cancer, Lyon, France.
Teresa RodríguezInternational Agency for Research on Cancer, Lyon, France.
Vivi SchlünssenInternational Agency for Research on Cancer, Lyon, France.
Lamia Benbrahim-TallaaInternational Agency for Research on Cancer, Lyon, France.
Aline de ContiInternational Agency for Research on Cancer, Lyon, France.
Caterina FacchinInternational Agency for Research on Cancer, Lyon, France.
Elisa PasqualInternational Agency for Research on Cancer, Lyon, France.
Roland WedekindInternational Agency for Research on Cancer, Lyon, France.
Ayat AhmadiInternational Agency for Research on Cancer, Lyon, France.
Shirisha ChittiboyinaInternational Agency for Research on Cancer, Lyon, France.
Zdenko HercegInternational Agency for Research on Cancer, Lyon, France.
Shalini KulasingamInternational Agency for Research on Cancer, Lyon, France.
Béatrice Lauby-SecretanInternational Agency for Research on Cancer, Lyon, France.
Richard MacLehoseInternational Agency for Research on Cancer, Lyon, France.
Moez SanaaInternational Agency for Research on Cancer, Lyon, France.
Joachim SchüzInternational Agency for Research on Cancer, Lyon, France.
Eero SuonioInternational Agency for Research on Cancer, Lyon, France.
Jiri ZavadilInternational Agency for Research on Cancer, Lyon, France.
Heidi MattockInternational Agency for Research on Cancer, Lyon, France.
Federica MadiaInternational Agency for Research on Cancer, Lyon, France.
Mary K Schubauer-BeriganInternational Agency for Research on Cancer, Lyon, France.

Funding

Research Services Supporting the Division of Translational ToxicologyZICES103380 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI HOOTH, MICHELLE · 2022 to 2025
$42.8M
EVALUATION OF CARCINOGENIC RISKS TO HUMANSU01CA033193 · NCI · INTERNATIONAL AGENCY FOR RES ON CANCER · PI SCHUBAUER-BERIGAN, MARY K. · 1985 to 2020
$16.5M
IARC Monographs on the Identification of Carcinogenic Hazards to HumansR01CA033193 · NCI · INTERNATIONAL AGENCY FOR RES ON CANCER · PI SCHUBAUER-BERIGAN, MARY K. · 2021 to 2025
$4.9M
NCI NIH HHS R01 CA033193World Health Organization 001
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NeoplasmsAdvisory CommitteesHealth PrioritiesHumans

Identifiers

PMID38621402
PMCPMC12640648

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.